Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group
Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), M. Babjuk(Charles University), Shilpa Gupta(Cleveland Clinic), Roger Buckley(Aurrion (United States)), Petros Grivas(Seattle Cancer Care Alliance), J. Alfred Witjes(Radboud University Nijmegen), Andrea B. Apolo(National Institutes of Health), Jason A. Efstathiou(Massachusetts General Hospital), Seth P. Lerner(Baylor College of Medicine), Peter C. Black(University of British Columbia), Donald L. Lamm(The University of Texas System), Roger Li(Unknown), Gary D. Steinberg(Rush University Medical Center), David J. McConkey(Johns Hopkins University), Éva Compérat(Vienna General Hospital), Trinity J. Bivalacqua(University of Pennsylvania), Joan Palou Redorta(Johns Hopkins University), Neal D. Shore(Carolina Urologic Research Center), Thomas Powles(Queen Mary University of London), Sarah P. Psutka(University of Washington Medical Center), Richard Sylvester(European Organisation for Research and Treatment of Cancer), Neil J. Kurtz(Tisch Cancer Institute), Matthew T. Campbell(The University of Texas MD Anderson Cancer Center)
Cited by 55
Related Papers
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Neurohumoral Features of Myocardial Stunning Due to Sudden Emotional Stress
|New England Journal of Medicine|2005|3.1k